StockNews.com assumed coverage on shares of Milestone Scientific (NYSE:MLSS - Free Report) in a report published on Friday. The firm issued a hold rating on the stock.
Separately, Benchmark initiated coverage on Milestone Scientific in a research report on Thursday, October 10th. They set a "speculative buy" rating and a $1.25 price objective for the company.
Check Out Our Latest Analysis on MLSS
Milestone Scientific Stock Performance
Shares of MLSS traded down $0.01 during trading hours on Friday, hitting $0.79. 65,640 shares of the company were exchanged, compared to its average volume of 101,830. The company has a market cap of $61.17 million, a PE ratio of -11.14 and a beta of 1.08. The firm's 50 day moving average is $0.94 and its 200-day moving average is $0.82. Milestone Scientific has a 52 week low of $0.52 and a 52 week high of $1.10.
Milestone Scientific (NYSE:MLSS - Get Free Report) last posted its quarterly earnings data on Thursday, August 15th. The company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.01). Milestone Scientific had a negative return on equity of 60.78% and a negative net margin of 54.87%. The business had revenue of $1.85 million for the quarter.
Insider Buying and Selling
In other Milestone Scientific news, Director Leonard Osser sold 107,984 shares of the company's stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $0.93, for a total value of $100,425.12. Following the completion of the transaction, the director now owns 4,606,882 shares of the company's stock, valued at $4,284,400.26. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In the last 90 days, insiders sold 251,106 shares of company stock valued at $236,451. Insiders own 24.75% of the company's stock.
Milestone Scientific Company Profile
(
Get Free Report)
Milestone Scientific Inc, a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments.
Further Reading
Before you consider Milestone Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Milestone Scientific wasn't on the list.
While Milestone Scientific currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
